Cognition Therapeutics CGTX
NASDAQ CGTX
$0.68 +0.01 (+1.06%)
At close: Nov 11, 2026 · 4:00 PM EST

Cognition Therapeutics (CGTX) Gains from Sales and Divestitures (2026)

Updated

Cognition Therapeutics' Gains from Sales and Divestitures was -$5,000 in Q1 2026.

Analysis

Cognition Therapeutics (CGTX) Gains from Sales and Divestitures (2026) Analysis & Trends

For FY2025, Gains from Sales and Divestitures at Cognition Therapeutics came in at -$41,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Cognition Therapeutics 63.72 Mn -68.99 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -5,000.00
API Access

Cognition Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CGTX&period=max&api_key=YOUR_API_KEY